证券代码：688363 证券简称：华熙生物 公告编号：2026-001 华熙生物科技股份有限公司 关于持股 5%以上股东权益变动触及 5%刻度 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 因实施本次减持计划，国寿成达权益变动触及 1%刻度的提示性公告请见公 司于 2025 年 11 月 28 日在上海证券交易所网站（www.sse.com.cn）披露的《华 熙生物科技股份有限公司关于持股 5%以上股东权益变动触及 1%刻度的提示性 公告》（公告编号：2025-045）。 本次权益变动为公司大股东国寿成达（上海）健康产业股权投资中心（有 限合伙）（以下简称"国寿成达"）根据公司于 2025 年 11 月 5 日在上 海证券交易所网站（www.sse.com.cn）披露的《华熙生物科技股份有限 公司股东减持股份计划公告》（公告编号：2025-043）（以下简称：本 次减持计划）作出的减持，不触及要约收购。 本次权益变动后国寿成达拥有权益的股份数量为 24,083,913 股，占公司 总股本的比 ...

Group 1 - The main subject of the equity change is Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership), with major partners including China Life Insurance Co., Ltd. (74.94%), China Life Insurance (Group) Company (16.65%), and China Life Property & Casualty Insurance Co., Ltd. (8.33%) [1] - The equity change involved a reduction from 28,936,504 shares (6.01% of total equity) to 24,083,913 shares (5.00% of total equity), resulting in a decrease of 4,852,591 shares, which is a reduction ratio of 1.0074% [1] - The reduction occurred between November 26, 2025, and January 7, 2026, through concentrated bidding for 2,844,591 shares (0.5906%) and block trading for 2,008,000 shares (0.4169%), with the shares being unrestricted circulating A-shares [1] Group 2 - The disclosed reduction plan has not been fully implemented, with a plan to reduce no more than 2.00% of the total equity by February 23, 2026, and there is a possibility of further reductions in the next 12 months [1]

Core Viewpoint - The major shareholder Guoshou Chengda of Huaxi Bio announced a share reduction plan, which will not change the company's controlling shareholder or actual controller [1] Group 1 - Guoshou Chengda plans to reduce its holdings from November 26, 2025, to January 7, 2026, by selling 2,844,591 shares through centralized bidding, accounting for 0.59% of the total shares [1] - On January 6, 2026, Guoshou Chengda will further reduce its holdings by selling 2,008,000 shares through block trading, representing 0.42% of the total shares [1] - The total reduction amounts to 4,852,591 shares, which is 1.01% of the total share capital [1] Group 2 - After the share reduction, Guoshou Chengda will hold 24,083,913 shares, which is approximately 5.00% of the total share capital [1] - The share reduction plan has not yet been fully implemented [1]

Group 1 - The medical beauty sector increased by 0.6% on January 8, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - The trading volume and turnover for key stocks in the medical beauty sector were reported, with Huaxi Biological closing at 45.11, up 1.12% [1] Group 2 - The net inflow of main funds in the medical beauty sector was 21.5 million yuan, while retail funds experienced a net outflow of 16.96 million yuan [1] - Detailed fund flow data showed that Aimeike had a main fund net inflow of 15.25 million yuan, while Huaxi Biological had a net inflow of 13.26 million yuan [2] - ST Meigu experienced a significant net outflow of main funds at 7.01 million yuan, indicating a negative trend in investor sentiment [2]

证券之星消息，1月7日医疗美容板块较上一交易日下跌0.74%，*ST美谷领跌。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗美容板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流出2679.3万元，游资资金净流入1374.35万元，散户 资金净流入1304.95万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资净流入 (元) 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 920982 锦波生物 | | | 2755.02万 | 12.55% | -1248.51万 | -5.69% | -439.98万 | -2.00% | | 688363 华熙生物 | | | 204.38万 | 1.30% | 771.92万 | 4. ...

Core Insights - The year 2025 has seen significant developments in the business landscape, with major companies like JD.com, ByteDance, and others making headlines for their innovative strategies and employee compensation initiatives [2] - The narrative emphasizes the dynamic nature of business, highlighting the importance of adaptability and innovation in a rapidly changing environment [2] Group 1: JD.com and Liu Qiangdong - Liu Qiangdong has made a strong public return in 2025, taking on the role of "Chief Experience Officer" and engaging directly with consumers through various initiatives [3][5] - His actions, such as cooking local dishes during live streams, signal a commitment to expanding JD.com's local service offerings and enhancing customer engagement [3][5] - Throughout the year, Liu has focused on employee welfare, announcing full social insurance coverage for delivery riders, thus redefining competition in the industry to include social responsibility [5][6] Group 2: Alibaba and Jiang Fan - Jiang Fan has returned to lead Alibaba's e-commerce division, focusing on integrating various business segments under a unified platform to enhance operational efficiency [7][9] - His strategy includes leveraging AI and real-time retail to drive growth, with significant improvements in user engagement and profitability reported [9] Group 3: Pop Mart and Wang Ning - Wang Ning has transformed Pop Mart into a leading player in the collectible toy market, with the LABUBU IP gaining significant popularity and driving stock prices to new highs [10][12] - Despite market concerns about sustainability, Pop Mart continues to innovate and expand its brand presence, including the introduction of luxury executives to its board [12] Group 4: AI and Yan Junjie - Yan Junjie, founder of MiniMax, has positioned the company as a leading player in the AI sector, focusing on high-efficiency algorithms and innovative approaches to model training [20][22] - MiniMax's recent IPO plans reflect its rapid growth and the increasing demand for AI solutions, with a strong emphasis on a youthful and efficient workforce [22][23] Group 5: Domestic Beauty and Zhao Yan - Zhao Yan of Huaxi Biological has been at the forefront of controversy and reform in the domestic beauty industry, actively addressing internal and external challenges [29][31] - Her leadership style emphasizes direct confrontation and accountability, aiming to reshape the company's culture and market position amidst ongoing scrutiny [31][32] Group 6: Old Puhuang and Xu Gaoming - Xu Gaoming's Old Puhuang brand has achieved remarkable sales performance, with projections indicating it may surpass major international luxury brands in revenue [33][34] - The brand's expansion into international markets, particularly Southeast Asia, marks a significant step in its growth strategy [36] Group 7: Live Streaming and Xin Ba - Xin Ba's decision to step back from live streaming reflects broader industry challenges, including personal health issues and shifts in business strategy [39][41] - The turmoil within his company highlights the transition of the live commerce sector from rapid growth to a more regulated and sustainable operational model [42]

华熙生物1月6日大宗交易平台共发生29笔成交，合计成交量200.80万股，成交金额8258.93万元。成交价 格均为41.13元，相对今日收盘价折价8.42%。从参与大宗交易营业部来看，机构专用席位共出现在12笔 成交的买方或卖方营业部中，合计成交金额为3352.12万元，净买入3352.12万元。 证券时报·数据宝统计显示，华熙生物今日收盘价为44.91元，上涨0.34%，日换手率为1.07%，成交额为 2.31亿元，全天主力资金净流入26.51万元，近5日该股累计上涨2.44%，近5日资金合计净流入181.68万 元。 两融数据显示，该股最新融资余额为5.17亿元，近5日减少763.08万元，降幅为1.45%。（数据宝） （文章来源：证券时报网） 北京建国门外大街证券营业 1月6日华熙生物大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日收 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额（万 | 格 | 盘折溢价 | 买方营业部 | 卖方营业部 | | 股） | 元） | （元） | （%） | | | | 16.50 | 678.65 ...

证券之星消息，1月6日医疗美容板块较上一交易日上涨0.66%，爱美客领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 146.49 | 1.06% | 3.41万 | 4.98 乙 | | 688363 | 华熙生物 | 44.91 | 0.34% | 5.16万 | 2.31亿 | | 920982 | 锦波生物 | 236.12 | -0.22% | 7324.94 | 1.74亿 | | 000615 | *ST美谷 | 3.46 | -0.86% | 13.90万 | 4782.12万 | 从资金流向上来看，当日医疗美容板块主力资金净流出1283.62万元，游资资金净流入772.62万元，散户 资金净流入511.0万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | 主力净占比 游资净流入 ...

Group 1 - The core viewpoint is that Huaxi Bio sees the South Korean market as a crucial area for international expansion, particularly in the rapidly growing medical aesthetics industry [2] - The China-Korea Business Forum highlighted discussions on manufacturing innovation, supply chain cooperation, and new consumer markets, with over 400 attendees from both countries [2] - Biomanufacturing is identified as a strategic high ground in the global technological revolution, with the "14th Five-Year Plan" emphasizing the need for forward-looking layouts in biomanufacturing and other future industries [2] Group 2 - Huaxi Bio, established in 2000 and listed on the STAR Market in 2019, specializes in the research and production of bioactive materials, holding a 44% share in the global hyaluronic acid raw material market and 70% in the domestic market [3] - The company entered the South Korean market in 2002 and has expanded into pharmaceuticals, medical aesthetics, cosmetics, and functional foods, with a new subsidiary established in Seoul in 2023 [3] - In the pharmaceutical sector, Huaxi Bio collaborates with top Korean companies in eye drops and joint injection products, while in medical aesthetics, its products cover over 90% of local production companies [3]

证券之星消息，1月5日医疗美容板块较上一交易日上涨2.22%，华熙生物领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 44.76 | 2.47% | 4.79万 | 2.14亿 | | 300896 | 爱美客 | 144.95 | 2.28% | 3.97万 | 5.72亿 | | 920982 | 锦波生物 | 236.64 | 1.26% | 7690.59 | 1.80 Z | | 000615 | *ST美谷 | 3.49 | 0.00% | 11.32万 | 3982.21万 | 从资金流向上来看，当日医疗美容板块主力资金净流入1362.9万元，游资资金净流出704.42万元，散户资 金净流出658.47万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345 ...